General Information of the Drug (ID: M6APDG03487)
Name
ISIS 104258
Status
Investigative
TTD Drug ID
D02AOC
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
RIP2 messenger RNA (RIP2 mRNA)
Wilms tumor 1-associating protein (WTAP)
In total 1 mechanisms lead to this potential drug response
Response Summary RIP2 messenger RNA (RIP2 mRNA) is a therapeutic target for ISIS 104258. The Wilms tumor 1-associating protein (WTAP) has potential in affecting the response of ISIS 104258 through regulating the expression of RIP2 messenger RNA (RIP2 mRNA). [1], [2]
References
Ref 1 Transcriptome-Wide High-Throughput m6A Sequencing of Differential m6A Methylation Patterns in the Human Rheumatoid Arthritis Fibroblast-Like Synoviocytes Cell Line MH7A. J Inflamm Res. 2021 Feb 25;14:575-586. doi: 10.2147/JIR.S296006. eCollection 2021.
Ref 2 The selectivity of protein kinase inhibitors: a further update. Biochem J. 2007 Dec 15;408(3):297-315. doi: 10.1042/BJ20070797.